← Return to all swing-trade opportunities
SYK — Oversold Bullish Reversal
Status: Invalidated
Scanner score: 35.0/100
Why this was flagged
SYK was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 35.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest stored daily low of 267.0000 reached or fell below stop loss 267.0234.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The computer program looked at Stryker Corp, which makes medical equipment. It found a pattern called an "Oversold Bullish Reversal." This means the stock price had dropped a lot recently. The scanner saw signs that the selling might be stopping. It noticed the stock was very weak, with a technical measure called RSI at 19.18. When RSI is that low, it often means the price has fallen too fast. The scanner also saw that more people were trading this stock than usual. Specifically, the trading activity was 1.36 times the normal amount. This extra attention made the scanner flag the stock for further watching.
What the price plan means
The scanner suggested a plan for trading the stock. The entry zone was between $275.46 and $278.08. This is where the system suggested looking at the price. The first goal, or target, was $292.33. The second goal was $300.77. To manage safety, the scanner set a stop-loss price at $267.02. If the price fell below this number, the idea would be considered broken. The plan offered a reward-to-risk ratio of 2. This means the potential gain was planned to be twice the amount of the possible loss. It is a way to balance risk and reward.
What could make the idea fail
Unfortunately, this specific plan is now marked as "invalidated." This means the setup did not work out as hoped. The latest daily low for the stock reached $267.00. This number is slightly below the stop-loss price of $267.02. When the price breaks below this safety line, the original logic for the trade no longer holds. The pattern has failed, so the previous plan is closed.
Important reminder
Stock prices change quickly. Past patterns do not guarantee future results. This explanation is for educational purposes only. It is not advice to buy or sell any stock. Always do your own research and consult a financial professional before making decisions with your money.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Caution (High confidence)
Stryker Corp shares fell 9.7% after management disclosed supply chain disruptions in its peripheral vascular business stemming from a March cyberattack and unexpectedly weak hip sales. These issues have led to downward revisions in 2026 revenue and EPS estimates from Wells Fargo and BMO Capital, who lowered their price targets to $348 and $317, respectively, despite maintaining positive ratings. While the company beat prior quarterly expectations, the operational setbacks have created uncertainty regarding future supply capabilities and customer acquisition. Counterbalancing this, Stryker is expanding its technology portfolio through a partnership with Duke Health to deploy augmented reality tools in hip surgeries, signaling continued innovation in its core medical device segments.
Potentially supportive context
- Stryker is collaborating with Duke Health to integrate augmented reality technology, specifically using Apple Vision Pro, to enhance precision in hip surgeries.
- Analysts such as Wells Fargo and BMO Capital maintain positive 'Overweight' and 'Outperform' ratings despite lowering their price targets due to current headwinds.
- The company recently reported Q2 2026 earnings that exceeded analyst expectations and raised its full-year guidance prior to the recent operational disclosures.
Risks and caution items
- The stock experienced a 9.7% decline after CFO Preston Wells reported that supply issues from a March cyberattack in the peripheral vascular business may extend into the fourth quarter.
- Hip sales were unexpectedly slower than anticipated, attributed to a softer European market, seasonality, and rising insurance deductibles in the U.S.
- BMO Capital and Wells Fargo both significantly reduced their 2026 revenue and EPS estimates following recent company conference presentations.
- Operational supply constraints may limit the company's ability to fully supply existing customers or attract new ones in the short term.
Latest reviewed article: Sep 11, 2026 4:26 am
Recent related articles
Dexcom, a global leader in glucose biosensing, announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein brings over 20 years of experience in the medical technology industry, having previously served as Vice President and CFO…
Stryker's stock fell 9.7% after CFO Preston Wells reported ongoing supply issues in its peripheral vascular business, stemming from a March cyberattack, and unexpectedly slower hip sales. The company had hoped to resolve the supply disruptions by the third quarter, but they…
Roper Technologies discussed its transformation into a vertical market software and technology company at Citi's 2026 Global TMT Conference, emphasizing strong margins and the integration of AI tools. The company outlined its strategy for future acquisitions, planning to deploy over $5 billion,…
Kestra Medical Technologies has appointed Daniel Finney as Vice President of Research & Development, succeeding Phillip D. Foshee, Jr. Finney, previously Senior Director of New Product Development, will oversee the Cardiac Recovery System platform, focusing on internal R&D, strategic partnerships, and AI…
BMO Capital has lowered its price target for Stryker Corp. (NYSE: SYK) to $317 from $369, while maintaining an Outperform rating. This adjustment follows revised estimates based on commentary from Stryker at a recent competitor conference, leading to reduced forecasts for third-quarter…
Mercury Systems EVP Steven Ratner recently sold 4,000 shares of the company's stock for $338,040, reducing his ownership by over 17%. This latest sale follows several other insider transactions in August, totaling over 10,000 shares sold as the stock's price declined. Despite…
Zacks Research has increased its Q1 2028 earnings per share estimate for Mercury Systems (NASDAQ: MRCY) to $0.24 from $0.23, maintaining a "Hold" rating, with a full-year consensus of $0.89. Despite recently missing EPS estimates but exceeding revenue expectations with $289.78 million,…
Wells Fargo has lowered its price target for Stryker (NYSE: SYK) to $348 from $418, citing concerns over future revenue growth, specifically reducing its 2026 revenue and EPS estimates below the company's guidance. This adjustment follows Stryker's presentation at a Wells Fargo…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Current volume is at least 1.25x the 20-day average volume.
- RSI is near oversold territory with bullish candle confirmation.